Investor Overview
News
- Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in DogsMarch 24, 2020 8:31 AM EDT
- Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial ResultsMarch 16, 2020 4:02 PM EDT
- Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial ResultsMarch 3, 2020 4:02 PM EST
Events
- Monday, March 16, 2020 4:30 PM EDT
- Monday, February 24, 2020 from 12:50 PM to 1:30 PM EST
- Wednesday, January 8, 2020 4:30 PM EST
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Investor Overview
KindredBio is focused on bringing breakthrough human products and innovative new technologies to veterinary medicine to address unmet clinical needs and provide benefits to animal co...
Stock Information
News
Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs
March 24, 2020
SAN FRANCISCO , March 24, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ...
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results
March 16, 2020
SAN FRANCISCO , March 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ...
Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results
March 3, 2020
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. P...